Clinical Trial Update: A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis [Phase 3]

View source ↗

Summary

An ongoing Phase 3 trial compares CT-P55, a secukinumab biosimilar, with Cosentyx (secukinumab) for moderate to severe plaque psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• CT-P55
• Cosentyx (secukinumab)

Snippet

Sponsor: Celltrion | Conditions: Plaque Psoriasis | Phase 3 | Status: ACTIVE_NOT_RECRUITING